Mobius Recalls Glaucoma Drug Due To Possible Yeast Contamination

Mitosol 011113

Pharmaceutical company Mobius Therapeutics LLC has initiated a voluntary recall of two lots of Mitosol, 0.2 mg/vial, Kit used in glaucoma surgery due to potential contamination with yeast.

The two lots in question can be identified through the lot numbers M098260 and M086920 with both bound to get expired in August this year. They were distributed between the dates October 22 and December 14 last year, in the states of Alabama, Arkansas, Delaware, Georgia, Illinois, Indiana, Massachusetts, Maryland, Maine, Michigan, Minnesota, Missouri, North Carolina, New Jersey, New York, Ohio, Pennsylvania, Tennessee, Wisconsin and Virginia, said the firm.

The company has warned that use of the potentially unsafe kits could lead to conditions as serious as loss of eyesight. It further said it has intimated recipients of the kits through phone calls, e-mails and written notifications regarding the speculation, in addition to making arrangements for return of unused products and replacing them with unaffected ones.

Mobius, which has insisted that people immediately stop using the potentially affected product, said it has not yet received any reports of adverse events related to the ongoing predicament.

The company can be contacted at 1-877-393-6484.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT